Story Stocks^®

Novartis (NVS) is up sharply after remibrutinib met the primary endpoint in both Phase III REMODEL trials, significantly reducing annualized relapse rates versus teriflunomide in relapsing multiple sclerosis while also demonstrating superiority across all key secondary endpoints within each study, including inflammatory MRI lesions. The results materially reduce development risk, but detailed efficacy magnitudes remain undisclosed and the disability-progression evidence came from a pooled analysis that produced only a positive trend at three months and nominal statistical significance at six months.

• REMODEL-1 and REMODEL-2 were identically designed, randomized, double-blind, active-comparator trials involving approximately 2,000 adults with relapsing MS. Two independently successful pivotal studies provide stronger regulatory evidence than a single positive trial or a result dependent entirely on pooled data.
• Remibrutinib reduced inflammatory brain lesions, providing objective support for the relapse findings. However, the three-month confirmed disability-progression endpoint did not achieve statistical significance, while the nominally significant six-month result was generated through a preplanned combined analysis, making the findings encouraging but not yet conclusive evidence of slowing disability.
• NVS reported that remibrutinib was well tolerated, with no liver safety signal and no cases meeting Hy’s Law criteria. That is particularly relevant given liver-toxicity concerns surrounding the BTK-inhibitor class, although complete infection, laboratory, adverse-event, and discontinuation data have not yet been disclosed.
• Remibrutinib is already approved as Rhapsido for chronic spontaneous urticaria, and its broader development program includes more than 4,500 participants, providing an established safety foundation. In MS, however, its eventual positioning will depend on whether the efficacy and convenience of an oral treatment compare favorably with anti-CD20 therapies and other emerging BTK inhibitors.
• Full results are scheduled for a late-breaking presentation at MSToronto 2026 on October 21-23, with an investor call afterward, while Novartis plans to seek regulatory approval globally. At the time of writing, the U.S.-listed ADRs were at $160.43, above their 50- and 200-day averages but below the $170.46 52-week high.

Briefing.com Analyst Insight

The central takeaway is that remibrutinib has cleared a major clinical hurdle through two independently positive Phase III trials, broad secondary-endpoint support, and a favorable preliminary safety profile. That combination improves the probability of regulatory approval and gives NVS a potentially differentiated oral MS therapy, but the announcement does not yet establish the magnitude of its commercial opportunity. Investors still need the absolute relapse rates, relative treatment effect, MRI lesion counts, disability hazard ratios, subgroup consistency, and complete safety tables before judging competitiveness against established high-efficacy treatments. The pooled disability findings also warrant restraint because nominal significance at six months is less robust than success within each independently powered study. The MSToronto presentation will therefore determine whether remibrutinib merely satisfied its pivotal program or demonstrated a benefit-risk profile capable of materially changing the MS treatment landscape.